“A meaningful first step in acknowledging decades of harm”: Lung Health Foundation Applauds Landmark $32.5 Billion Legal Settlement Against Tobacco Companies
October 18, 2024 14:10 ET
|
Lung Health Foundation
Lung Health Foundation- Canada’s premier resource on lung health research, education and advocacy- applauds Landmark Settlement Against Tobacco Companies
Global Nebulizer Market Size Projected to Reach USD 2.05 Billion by 2032, Growing at 6.57% CAGR – SNS Insider
October 18, 2024 09:00 ET
|
SNS Insider pvt ltd
Austin, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Nebulizer Market Size Analysis: "According to SNS Insider, The Nebulizer Market was valued at USD 1.16 Billion in 2023 and is projected to reach USD 2.05...
Bilevel Positive Pressure Ventilator Market to Reach $3.4 Billion, Globally, by 2033 at 5.9% CAGR: Allied Market Research
October 03, 2024 10:06 ET
|
Allied Analytics LLP
Wilmington, Delaware, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Bilevel Positive Pressure Ventilator Market by Type (Fixed Pressure BiPAP Device and Auto...
Monaghan Medical Wins 2024 AARC Zenith Award
October 03, 2024 04:00 ET
|
Monaghan Medical Corporation
Monaghan Medical Corporation has been honored with the prestigious 2024 Zenith Award from the American Association for Respiratory Care (AARC). This award
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
September 27, 2024 09:35 ET
|
Regeneron Pharmaceuticals, Inc.
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
September 27, 2024 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...
Vaping Expected to Increase COPD Health and Economic Burden by 2050
September 10, 2024 08:00 ET
|
ResMed Inc.
Vaping Expected to Increase COPD Health and Economic Burden by 2050
New ResMed-supported research presented at ERS 2024
Wellinks Recognized as Quarterfinalist for the Digital Health Hub Foundation: Digital Health Awards
September 04, 2024 11:00 ET
|
Wellinks Inc.
NEW HAVEN, Conn., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Wellinks, is thrilled to announce its selection as a quarterfinalist for the prestigious 2024 Digital Health Hub Foundation: Digital Health...
Innovative New COPD Maintenance Treatment Now Available Through DirectRx Specialty Pharmacy
August 28, 2024 11:51 ET
|
DirectRx Pharmacy
DirectRx selected for exclusive distribution network for the newest and first-in-class COPD medication, Ohtuvayre by Verona Pharma
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
August 26, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from...